Title: Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration
Authors: Kantor, Rami ×
Katzenstein, David A
Efron, Brad
Carvalho, Ana Patricia
Wynhoven, Brian
Cane, Patricia
Clarke, John
Sirivichayakul, Sunee
Soares, Marcelo A
Snoeck, Joke
Pillay, Candice
Rudich, Hagit
Rodrigues, Rosangela
Holguin, Africa
Ariyoshi, Koya
Bouzas, Maria Belen
Cahn, Pedro
Sugiura, Wataru
Soriano, Vincent
Brigido, Luis F
Grossman, Zehava
Morris, Lynn
Vandamme, Anne-Mieke
Tanuri, Amilcar
Phanuphak, Praphan
Weber, Jonathan N
Pillay, Deenan
Harrigan, P Richard
Camacho, Ricardo
Schapiro, Jonathan M
Shafer, Robert W #
Issue Date: Apr-2005
Publisher: Public Library of Science
Series Title: PLoS Medicine vol:2 issue:4 pages:325-337
Abstract: BACKGROUND: The genetic differences among HIV-1 subtypes may be critical to clinical management and drug resistance surveillance as antiretroviral treatment is expanded to regions of the world where diverse non-subtype-B viruses predominate. METHODS AND FINDINGS: To assess the impact of HIV-1 subtype and antiretroviral treatment on the distribution of mutations in protease and reverse transcriptase, a binomial response model using subtype and treatment as explanatory variables was used to analyze a large compiled dataset of non-subtype-B HIV-1 sequences. Non-subtype-B sequences from 3,686 persons with well characterized antiretroviral treatment histories were analyzed in comparison to subtype B sequences from 4,769 persons. The non-subtype-B sequences included 461 with subtype A, 1,185 with C, 331 with D, 245 with F, 293 with G, 513 with CRF01_AE, and 618 with CRF02_AG. Each of the 55 known subtype B drug-resistance mutations occurred in at least one non-B isolate, and 44 (80%) of these mutations were significantly associated with antiretroviral treatment in at least one non-B subtype. Conversely, of 67 mutations found to be associated with antiretroviral therapy in at least one non-B subtype, 61 were also associated with antiretroviral therapy in subtype B isolates. CONCLUSION: Global surveillance and genotypic assessment of drug resistance should focus primarily on the known subtype B drug-resistance mutations.
ISSN: 1549-1676
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Clinical and Epidemiological Virology (Rega Institute)
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science